Filter Results:
(1,246)
Show Results For
- All HBS Web
(1,246)
- People (5)
- News (171)
- Research (929)
- Events (6)
- Multimedia (12)
- Faculty Publications (758)
Show Results For
- All HBS Web
(1,246)
- People (5)
- News (171)
- Research (929)
- Events (6)
- Multimedia (12)
- Faculty Publications (758)
- 31 Oct 2023
- News
Securing a Resilient Future for Senegal
Sijh Diagne (photo by Michael Bucher) In March 2020, Sijh Diagne (MBA 2017) was asked to serve as an advisor to Senegal’s minister of economy, planning, and cooperation. He was charged with leading the country’s private-sector development; but just as became the case... View Details
- 19 Apr 2004
- Research & Ideas
Birth of the American Salesman
This figure includes all types of sellers, from pharmaceutical sales workers to counterpersons at department stores; it is up from about 5 percent in 1920 and 7 percent in 1960. Of the 16 million people working in sales in 2000, about 10... View Details
Keywords: by Laura Linard
- 01 Feb 2022
- Book
Innovation Isn’t Just for Startups: How Big Companies Can Succeed
traditional core. She hired computational chemists, genetic scientists, and pharmaceutical business experts. They dressed and spoke differently from the famously staid IBM executive. The best Corporate Explorers not only disrupt the... View Details
Keywords: by Lane Lambert
- Web
For Recruiters - Health Care
systems, e-health firms, pharmaceutical companies, medical device manufacturers, and biotechnology companies. Hire a Summer Intern Summer internships are valuable for both employers and students as a “test run.” Employers benefit most... View Details
- 2013
- Working Paper
International Health Economics
By: Mark Egan and Tomas J. Philipson
Perhaps because health care is a local service sector, health economists have paid little attention to international linkages between domestic health care economies. However, the growth in domestic health care sectors is often attributed to medical innovations whose... View Details
Egan, Mark, and Tomas J. Philipson. "International Health Economics." NBER Working Paper Series, No. 19280, August 2013.
- 15 Nov 2018
- Book
Can the Global Food Industry Overcome Public Distrust?
JamesBrey Food is the largest segment of the global economy. It is also widely recognized as more critical for human health than any pharmaceutical drug on the planet. But significant changes in the industry are making people lose trust in many institutions involved in... View Details
- February 2024
- Case
Compass Pathways: Pioneering Psychedelic Treatment
By: Tiona Zuzul, Kisha Lashley and Gamze Yucaoglu
This case follows Compass Pathways, a pioneering company developing treatment for depression based on psilocybin, the compound found in ‘magic mushrooms.’ Psilocybin was a federally illegal substance in the U.S., and a “Schedule I” drug, defined as a drug “with no... View Details
Keywords: Commercialization; Corporate Strategy; Competitive Strategy; Product Launch; Health Testing and Trials; Research and Development; Laws and Statutes; Pharmaceutical Industry; Europe; United States; United Kingdom
Zuzul, Tiona, Kisha Lashley, and Gamze Yucaoglu. "Compass Pathways: Pioneering Psychedelic Treatment." Harvard Business School Case 724-412, February 2024.
- February 2010 (Revised September 2011)
- Case
Roche's Acquisition of Genentech
By: Carliss Y. Baldwin, Bo Becker and Vincent Marie Dessain
Franz Humer, CEO of the Roche Group, must decide whether to mount a hostile tender offer for the publicly-owned shares of Roche's biotechnology subsidiary, Genentech. The case provides opportunities to analyze Roche's strategy with respect to Genentech, the pros and... View Details
Keywords: Mergers and Acquisitions; Business Subsidiaries; Negotiation Offer; Organizational Culture; Corporate Strategy; Pharmaceutical Industry; Pharmaceutical Industry; Switzerland
Baldwin, Carliss Y., Bo Becker, and Vincent Marie Dessain. "Roche's Acquisition of Genentech." Harvard Business School Case 210-040, February 2010. (Revised September 2011.)
John T. Gourville
John Gourville is the Albert J. Weatherhead, Jr. Professor of Business Administration at the Harvard Business School. He joined the HBS Marketing Unit in 1995 after receiving his Ph.D. at the University of Chicago in marketing and behavioral research. His most... View Details
- December 2019
- Case
The Business of Pain: Johnson & Johnson and the Promise of Opioids
By: Erik Snowberg, Trevor Fetter and Amy W. Schulman
This case is designed to provide an engrossing overview of stakeholder capitalism through a vigorous discussion of the conflicts that can arise when trying to serve multiple stakeholders.
In 2007, Johnson & Johnson’s (J&J) subsidiary Janssen has to decide whether or... View Details
Keywords: Opioids; Addiction; Stakeholder Capitalism; Business and Stakeholder Relations; Product Launch; Decision Making; Ethics; Social Issues; Pharmaceutical Industry
Snowberg, Erik, Trevor Fetter, and Amy W. Schulman. "The Business of Pain: Johnson & Johnson and the Promise of Opioids." Harvard Business School Case 720-420, December 2019.
- October 2022
- Case
Cost Plus Drugs
By: Alexander MacKay and James Barnett
In September 2022, Mark Cuban Cost Plus Drugs Company CEO Alex Oshmyansky considered the future of the company. Cost Plus Drugs was a retailer for more than 340 generic oral medications, selling their drugs at significantly lower prices than typical pharmacies.... View Details
Keywords: Business Ventures; Decision Making; Entrepreneurship; Ethics; Health; Markets; Social Enterprise; Society; Strategy; Health Care and Treatment; Business Divisions; Factories, Labs, and Plants; Pharmaceutical Industry; Pharmaceutical Industry; United States; Texas
MacKay, Alexander, and James Barnett. "Cost Plus Drugs." Harvard Business School Case 723-362, October 2022.
- March 2023 (Revised March 2023)
- Case
Roche: Innovation and Access to Healthcare
By: George Serafeim, Susanna Gallani and Benjamin Maletta
In May 2022, Roche Group, one of the largest healthcare companies in the world, hosted its first investor event focused exclusively on its efforts to impact access to healthcare. While Roche had recently set an ambitious goal to double the number of patients that had... View Details
Keywords: ESG (Environmental, Social, Governance) Performance; Sustainable Finance; Growth Strategy And Execution; Sustainability Targets; Impact Evaluation; Healthcare Access; Healthcare Innovation; Healthcare Systems; Healthcare Operations; Finance; Strategy; Health Testing and Trials; Health Care and Treatment; Growth Management; Measurement and Metrics; Innovation Strategy; Corporate Social Responsibility and Impact; Pharmaceutical Industry; Pharmaceutical Industry; Switzerland; North America; Europe; Asia; Latin America; Africa
Serafeim, George, Susanna Gallani, and Benjamin Maletta. "Roche: Innovation and Access to Healthcare." Harvard Business School Case 123-075, March 2023. (Revised March 2023.)
- 10 Apr 2014
- Research & Ideas
John Kotter’s Plan to Accelerate Your Business
other more rational. In a typical organization—from the federal government to a pharmaceutical giant—a hierarchical operational structure meets daily demands through clear reporting relationships and responsibilities, Kotter writes. This... View Details
Keywords: by Kim Girard
- July 2001 (Revised August 2005)
- Case
Medicines Company, The
It is early 2001 and the Medicines Co. just received FDA approval to market Angiomax, a blood thinner to be used during angioplasties and heart procedures. It is intended to be a better alternative to Heparin, an 80-year-old drug that costs less then $10 per dose. The... View Details
Keywords: Business Model; Change Management; Decision Choices and Conditions; Cost Management; Price; Product Marketing; Product Launch; Product Development; Risk and Uncertainty; Pharmaceutical Industry; Pharmaceutical Industry
Gourville, John T. "Medicines Company, The." Harvard Business School Case 502-006, July 2001. (Revised August 2005.)
- January 1998 (Revised February 2006)
- Background Note
Creating Competitive Advantage
By: Pankaj Ghemawat and Jan W. Rivkin
A firm such as Schering-Plough that earns superior, long-run financial returns within its industry is said to enjoy a competitive advantage over its rivals. This note examines the logic of how firms create competitive advantage. It emphasizes two themes: First, to... View Details
Keywords: Competitive Advantage; Competitive Strategy; Management; Business Strategy; Growth and Development Strategy; Innovation Strategy; Management Practices and Processes; Value Creation; Pharmaceutical Industry
Ghemawat, Pankaj, and Jan W. Rivkin. "Creating Competitive Advantage." Harvard Business School Background Note 798-062, January 1998. (Revised February 2006.)
- 01 Dec 2019
- News
Remix
exercise of getting the mix just right “had almost a pharmaceutical effect on me,” she says. Hip-hop, though, hit a nerve. “I liked the nerdy braininess of digging into the lyrics and wordplay, but it also mashed up the soundtrack of my... View Details
- September 2010 (Revised July 2013)
- Case
Alnylam Pharmaceuticals: Building Value from the IP Estate
By: Willy C. Shih and Sen Chai
The learning objective of this case is to help students recognize the interplay between intellectual property (IP) rights and corporate strategy. We do this by examining what is a fairly atypical circumstance today in which a single firm is able to secure what it... View Details
Keywords: Patents; Lawsuits and Litigation; Rights; Competitive Strategy; Corporate Strategy; Pharmaceutical Industry; Pharmaceutical Industry; United States
Shih, Willy C., and Sen Chai. "Alnylam Pharmaceuticals: Building Value from the IP Estate." Harvard Business School Case 611-009, September 2010. (Revised July 2013.)
- 22 Aug 2022
- Research & Ideas
Can Amazon Remake Health Care?
How are they going to use it? What safeguards will patients in this new Amazon/One Medical health care have on how their data will be used? I would like regulators to think about and wrestle with that issue. “Amazon is good at selling other people’s products—but I... View Details
Elon Kohlberg
Elon Kohlberg is the Royal Little Professor of Business Administration at the Harvard Business School. His research is mainly in Game Theory, in particular the study of non-cooperative equilibrium.
Professor Kohlberg has taught many courses in the MBA,... View Details
- 22 Nov 2004
- Research & Ideas
Side Effects: The Case of Propecia
You are the marketing director of Propecia, a new drug for hair restoration that's about to hit the market. But the drug can only be purchased via a physician's prescription. So do you advertise directly to balding men? Do you concentrate on targeting physicians? How... View Details